BioCentury

8:00 AM GMT, Feb 28, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Votrient pazopanib regulatory update

The U.K.'s NICE issued final guidance recommending the use of Votrient pazopanib from GlaxoSmithKline as a first-line

Read the full 175 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.